Successful Rechallenge of Trastuzumab Deruxtecan After Drug-Induced Interstitial Lung Disease in a NSCLC With HER2 Mutation: A Case Report
Trastuzumab deruxtecan, an antibody-drug conjugate targetingHER2-expressing tumor cells, was found to have promising results in treatment-refractory, metastatic NSCLC harboring HER2 mutations. Nevertheless, drug-induced interstitial lung disease (ILD)/pneumonitis is a concern that limits treatment r...
Сохранить в:
| Главные авторы: | , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Elsevier
2024-02-01
|
| Серии: | JTO Clinical and Research Reports |
| Предметы: | |
| Online-ссылка: | http://www.sciencedirect.com/science/article/pii/S2666364323001716 |
| Метки: |
Нет меток, Требуется 1-ая метка записи!
|